In DSS-induced experimental colitis the administration of IL-18BP or the neutralization of IL-18 was able to attenuate intestinal inflammation and weight loss (Siegmund et al., 2001; Sivakumar et al., 2002; Siegmund et al., 2004). The gene discussed is IL18; the disease is gastroenteritis.